newsfilter
← Latest News
PR Newswire·

Stealth BioTherapeutics Granted Pre-NDA Meeting for Elamipretide as a Potential Treatment for Barth Syndrome

Type B meeting scheduled with FDA Division of Cardiology and Nephrology Company plans to discuss new clinical data that may inform a potential NDA submission BOSTON, June 14, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO), a clini